Identification of ISCA1 as novel immunological and prognostic biomarker for bladder cancer

被引:2
|
作者
Zhou, Renlong [1 ]
Peng, Naixiong [2 ]
Li, Wei [2 ]
机构
[1] Shenzhen Longhua Dist Cent Hosp, Dept Blood Transfus, Shenzhen, Peoples R China
[2] Shenzhen Longhua Dist Cent Hosp, Dept Urol, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
pan-cancer; ISCA1; BLCA; GSEA; immune microenvironment; prognostic analysis; IMMUNE CHECKPOINT INHIBITORS; CELLS; CARCINOMA;
D O I
10.3389/fimmu.2022.975503
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundIron-sulfur cluster assembly 1 (ISCA1) has a significant effect on respiratory complexes and energy metabolism. Although there is some evidence that ISCA1 gene expression impacts energy metabolism and consequently has a role in tumorigenesis and cancer metastasis in different types of malignancies, no systematic pan-cancer study of the ISCA1 has been conducted. As a result, we sought to investigate ISCA1's predictive value in 33 cancer types as well as its possible immunological function. MethodsWe included the pan-cancer expression profile dataset and clinical data from the public database. Firstly, the single-sample Gene Set Enrichment Analysis (ssGSEa) approach was employed for analyzing the immune link in pan-cancer, while the limma package was utilized for analyzing the differential expression in cancer species. Subsequently, ciberport, MCP-counter, TIMER2, quanTIseq, and xCELL were employed for analyzing bladder cancer (BLCA)'s immune infiltration. Least absolute shrinkage and selection operator (Lasso) were employed for choosing the best gene to develop the immune risk scoring model. ResultsISCA1 gene expression was positively related to four immune signatures (chemokine, immunostimulator, MHC, and receptor) in BLCA. Samples of BLCA were sorted into two groups by the best cut-off of ISCA1 expression degree. The group with a high level of ISCA1 expression had a higher risk, suggesting that the ISCA1 gene was a risk factor in BLCA, and its high expression resulted in a poorer prognosis. Additionally, it was noted that ISCA1 was positively linked with these immune checkpoints. Moreover, there was a considerable positive link between ISCA1 and different immune properties in subgroups with different immune checkpoint inhibiting responses. Finally, an immune risk scoring model was made and it showed a better score in comparison to that of TIDE. ConclusionISCA1 can be a prognostic marker for a variety of cancers, particularly BLCA. Its high level of expression has a deleterious impact on the prognosis of BLCA patients. This strongly shows that ISCA1 is a significant prognostic factor for BLCA and that it could be used as a new prognostic detection target and treatment approach.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] ISCA1 could serve as a prognostic biomarker for patients with kidney renal clear cell carcinoma
    Zhou, Renlong
    Zhang, Cantong
    ASIAN JOURNAL OF SURGERY, 2025, 48 (03) : 1972 - 1974
  • [2] CXCL10 could be a prognostic and immunological biomarker in bladder cancer
    Yin, Tao
    Mou, Shuanzhu
    Zhang, Haiyu
    Dong, Ying
    Yan, Bing
    Huang, Weisheng
    Liu, Yuhan
    Mei, Hongbing
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [3] Identification of a three miRNA signature as a novel potential prognostic biomarker in patients with bladder cancer
    Peng, Fei
    Li, Hui
    Xiao, Hailang
    Li, Ling
    Li, Yan
    Wu, Yi
    ONCOTARGET, 2017, 8 (62) : 105553 - 105560
  • [4] Identification and validation of SERPINE1 as a prognostic and immunological biomarker in pan-cancer and in ccRCC
    Li, Lingqin
    Li, Fan
    Xu, Zhehao
    Li, Liyang
    Hu, Haiyi
    Li, Yang
    Yu, Shicheng
    Wang, Mingchao
    Gao, Lei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [5] Identification of NBS1 as a novel prognostic biomarker in BRCAness ovarian cancer
    Lee, Y.
    Park, N.
    Chung, H.
    Kim, J.
    Song, Y.
    Kang, S.
    Lee, H.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S6 - S6
  • [6] Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer
    Zhengnan Huang
    Yilin Yan
    Tengjiao Wang
    Zeyi Wang
    Jinming Cai
    Xiangqian Cao
    Chenkai Yang
    Fang Zhang
    Gang Wu
    Bing Shen
    Journal of Translational Medicine, 20
  • [7] Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer
    Huang, Zhengnan
    Yan, Yilin
    Wang, Tengjiao
    Wang, Zeyi
    Cai, Jinming
    Cao, Xiangqian
    Yang, Chenkai
    Zhang, Fang
    Wu, Gang
    Shen, Bing
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [8] Integrative analysis of circadian clock with prognostic and immunological biomarker identification in ovarian cancer
    Zhao, Lianfang
    Tang, Yuqin
    Yang, Jiayan
    Lin, Fang
    Liu, Xiaofang
    Zhang, Yongqiang
    Chen, Jianhui
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [9] Comprehensive Analysis Reveals That ISCA1 Is Correlated with Ferroptosis-Related Genes Across Cancers and Is a Biomarker in Thyroid Carcinoma
    Xiong, Dejun
    Li, Zhao
    Zuo, Ling
    Ge, Juan
    Gu, Yuhan
    Zhang, Erhao
    Zhou, Xiaorong
    Yu, Guiping
    Sang, Mengmeng
    GENES, 2024, 15 (12)
  • [10] Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer
    Shimpei Yamashita
    Yuya Iwahashi
    Haruka Miyai
    Takashi Iguchi
    Hiroyuki Koike
    Satoshi Nishizawa
    Nagahide Matsumura
    Keizo Hagino
    Kazuro Kikkawa
    Yasuo Kohjimoto
    Isao Hara
    Scientific Reports, 10